

1 **Title**

2 *Streptococcus pyogenes* M1T1 variants activate caspase-1 and induce an inflammatory neutrophil  
3 phenotype

4 **Authors/Affiliations**

5 Jonathan G. Williams<sup>1,2</sup>, Diane Ly<sup>1,2</sup>, Nicholas J. Geraghty<sup>1,2</sup>, Jason D. McArthur<sup>1,2</sup>, Heema K. N.  
6 Vyas<sup>1,2</sup>, Jody Gorman<sup>1,2</sup>, James A. Tsatsaronis<sup>3</sup>, Ronald Sluyter<sup>1,2</sup>, Martina L. Sanderson-Smith<sup>1,2,4,\*</sup>

7 <sup>1</sup>Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia.

8 <sup>2</sup>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of  
9 Wollongong, Wollongong, New South Wales, Australia.

10 <sup>3</sup>College of Science, Health and Engineering, La Trobe University, Bundoora, Victoria, Australia.

11 <sup>4</sup>Lead contact

12 **Contact Info**

13 \*Correspondence: Illawarra Health and Medical Research Institute (IHMRI), School of Chemistry  
14 and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia. E-mail:  
15 [martina@uow.edu.au](mailto:martina@uow.edu.au)

16 **Summary**

17 Invasive infections due to Group A *Streptococcus* (GAS) advance rapidly causing tissue  
18 degradation and unregulated inflammation. Neutrophils are the primary immune cells that  
19 respond to GAS. The neutrophil response to GAS was characterised in response to two M1T1  
20 isolates; 5448 and animal passaged variant 5448AP. Neutrophil co-incubation with 5448AP  
21 allowed proliferation of GAS while it also lowered the production of reactive oxygen species by  
22 neutrophils when compared with 5448. Infection with both strains invoked neutrophil death,  
23 however apoptosis was reduced in response to 5448AP. Both strains induced neutrophil caspase-

24 1 activation and caspase-4 expression *in vitro*, with caspase-1 activation detected *in vivo*. Thus,  
25 GAS infection of neutrophils corresponds to increased caspase-1 activity and caspase-4  
26 expression, consistent with inflammasome activation and pyroptosis. GAS infections that  
27 promote an inflammatory neutrophil phenotype may contribute to increased inflammation yet  
28 ineffective bacterial eradication, contributing to the speed and severity of invasive GAS infections.

29 **Keywords**

30 Polymorphonuclear leukocyte, PMN, apoptosis, pyroptosis, caspase-1, caspase-3, caspase-4,  
31 CD16, CD31, CD66b, CD11b, IL-1 $\beta$ , TNF- $\alpha$ , IL-8, IL-18, cell-death, *covS*, 5448, 5448AP,  
32 LEGENDplex, FLICA, inflammation, inflammasome

33 **Introduction**

34 Invasive infections due to the obligate human pathogen *Streptococcus pyogenes* (Group A  
35 *Streptococcus*; GAS) are characterised by unregulated inflammation and high mortality (Davies et  
36 al., 1996, Lamagni et al., 2008, Nelson et al., 2016, O'Grady et al., 2007, O'Loughlin et al., 2007,  
37 Svensson et al., 2000). The highly virulent GAS M1T1 clone 5448 is well studied (Aziz and Kotb,  
38 2008, Tart et al., 2007, Walker et al., 2007). The propensity of M1T1 GAS to cause invasive  
39 infections is due, in part, to the increased frequency of spontaneous mutations in the two-  
40 component control of virulence regulatory system (*covRS*) (Walker et al., 2007), resulting in  
41 differential expression of multiple virulence factors, many of which are implicated in immune  
42 defence (Kilsgård et al., 2016, Sumby et al., 2005, Sumby et al., 2006, Walker et al., 2007).  
43 Compelling evidence describes the resistance of *covS* mutant GAS (mutation to the sensor protein  
44 of *covRS*) to killing by human neutrophils (polymorphonuclear leukocytes, PMNs) (Ato et al.,  
45 2008, Maamary et al., 2010, Walker et al., 2007). 5448AP (animal passaged) is one M1T1 *covS*  
46 mutant strain that shows resistance to killing by human neutrophils, has increased bacterial  
47 dissemination and results in decreased survival in mouse models of infection (Fiebig et al., 2015,

48 Maamary et al., 2010, Walker et al., 2007). Due to these characteristics, 5448AP can be used as a  
49 model strain to explore the host response to invasive GAS infection.

50 Neutrophils are the primary innate immune cell-type that defend against bacterial pathogens,  
51 with their presence contributing to the overarching inflammatory response (Kobayashi et al.,  
52 2018). Proteins of neutrophil origin are highly abundant at sites of invasive GAS infection  
53 (Edwards et al., 2018). The neutrophil life cycle is tightly regulated to avoid the release of  
54 cytotoxic contents that can damage surrounding tissue and contribute further to inflammation  
55 (Epstein and Weiss, 1989, Faurschou and Borregaard, 2003). Under normal conditions cytotoxic  
56 reactive oxygen species (ROS) produced by neutrophils kill phagocytosed bacteria (Nguyen et al.,  
57 2017). An increased production of ROS signals for the induction of the anti-inflammatory cell-  
58 death pathway apoptosis (Lundqvist-Gustafsson and Bengtsson, 1999). During apoptosis,  
59 neutrophils are carefully decommissioned, ensuring no unregulated release of intracellular  
60 material, then cleared by a secondary phagocyte, macrophages, through a process known as  
61 efferocytosis (Bratton and Henson, 2011). The cleavage of caspase-3 to the p17 form denotes the  
62 execution of apoptosis (Nicholson et al., 1995). Increased neutrophil apoptosis is described  
63 during GAS infection (Kobayashi et al., 2003). Pro-inflammatory neutrophil death has also been  
64 reported during GAS infection (Tsatsaronis et al., 2015). One form of pro-inflammatory death is  
65 pyroptosis, involving the formation of an inflammasome and subsequent caspase-1 or caspase-4  
66 activation, culminating in cell-lysis (Man and Kanneganti, 2016, Sollberger et al., 2012).  
67 Deregulation of (or excessive) pro-inflammatory neutrophil-death may therefore contribute  
68 further to inflammatory pathology, as demonstrated during infection with other pathogens,  
69 including *Pseudomonas aeruginosa* (Ryu et al., 2017) and *Staphylococcus aureus* (Ghimire et al.,  
70 2018, Greenlee-Wacker et al., 2017, Ryu et al., 2017). Inflammation is also heavily influenced by  
71 cell cytokine production, where increased release can invoke neutrophil dysfunction, affecting  
72 neutrophil survival, antibacterial function or even migration (Brown et al., 2006, Kipnis, 2013,  
73 Kovach and Standiford, 2012, Norrby-Teglund et al., 2000). Previous work outlines how GAS take  
74 advantage of inadequate or exacerbated immune responses and focus upon the bacterial


75 mechanisms involved (Cole et al., 2011). Although models to investigate leukocyte inflammasome  
76 activation have been proposed (Tran et al., 2019), a limited number of studies have investigated  
77 the neutrophil response to GAS specifically (Kobayashi et al., 2003). Here, using an *in vitro* model,  
78 we temporally describe the effect two M1T1 GAS strains have upon human neutrophil death,  
79 signalling and inflammatory profile. We further characterise this interaction in murine  
80 neutrophils, using an *in vivo* model of intradermal invasive GAS infection. Additionally, we  
81 identify differences in the neutrophil response to GAS due to *covS* mutation. We hypothesise that  
82 changes to neutrophil function by GAS can promote invasive GAS infection by exacerbating the  
83 inflammatory response, decreasing antibacterial capacity and inducing inflammatory neutrophil  
84 death.

85 **Results**

86 **GAS persistence and proliferation occurs during a damped neutrophil ROS response**

87 Neutrophil phagocytic ability is a predominant and well-established mechanism of immune  
88 defence. Both GAS strains 5448 and 5448AP rapidly associated with human neutrophils, with  
89 near maximal association observed within 30 min (Figures 1A and S1A-C). Higher percentages of  
90 neutrophils were associated with 5448 compared to 5448AP (Figure 1A). 5448 and 5448AP also  
91 induced ROS production in neutrophils, with less ROS produced by neutrophils incubated in the  
92 presence and absence of 5448AP compared to those incubated with 5448 (Figure 1B). As such,  
93 the rate of neutrophil ROS production was significantly increased compared to the neutrophil  
94 only control during 5448, but not 5448AP, infection ( $p < 0.01$ , Figure S1D), suggesting damped  
95 antibacterial function in neutrophils in response to 5448AP. This difference in GAS-induced ROS  
96 production inversely corresponded to GAS proliferation in the presence of neutrophils, with high  
97 numbers of 5448AP observed compared to 5448 over 180 min (Figure 1C). Differential GAS  
98 proliferation required viable neutrophils, as 5448 and 5448AP proliferation in the presence of  
99 neutrophil lysates was reduced and similar for both strains over 180 min (Figure 1D). Finally,  
100 incubation of neutrophils with the phagocytosis inhibitor cytochalasin D significantly increased

101 5448, but not 5448AP, survival ( $p<0.001$ , Figure S1E), indicating that 5448 killing is  
102 predominantly mediated via a phagocytic-related pathway. Collectively, these data indicate that  
103 compared to 5448, 5448AP associates less readily with human neutrophils leading to reduced  
104 ROS production and increased survival of this strain.



105 **Figure 1. GAS persistence and proliferation occurs during a dampened neutrophil ROS**  
106 **response.** (A) Association of fluorescent GAS strains with human neutrophils (PMNs,  $n=6$   
107 donors), analysed via flow cytometry (Figure S1A-B). (B) Infection of human neutrophils with  
108 GAS invokes ROS production. Representative of triplicate measurements from three separate  
109 experiments ( $n=3$  donors), shown as mean change in fluorescence units over time ( $\Delta F \cdot \text{min}^{-1}$ ). GAS  
110 strains were incubated in the presence of (C) human neutrophils ( $n=8$  donors) or (D) lysed  
111 human neutrophils ( $n=4$  donors) over 180 min with surviving bacterial concentration  
112 determined as percentage of inoculum. Results are the pooled means $\pm$ SD (of triplicate  
113 measurements for panels C and D). \*\* $p<0.01$  and \*\*\*\* $p<0.0001$ .

114 **Neutrophil death is delayed during infection with 5448AP**

115 GAS can induce death of human neutrophils (Kobayashi et al., 2003, Tsatsaronis et al., 2015),  
116 however the mechanism remains poorly described. Phosphatidylserine (PS) exposure is a


117 hallmark of the induction of multiple death pathways including apoptosis and pyroptosis (Man  
118 and Kanneganti, 2016, Wang et al., 2013). Human neutrophils were incubated with 5448, 5448AP  
119 or in the absence of GAS then the binding of annexin-V (AV), as a measure of PS exposure, and the  
120 binding of Zombie Fixable Viability Kit (Z), as a measure of membrane integrity, were analysed  
121 by flow cytometry (Figure 2). Cells were defined as viable (AV-Z-), PS exposed (AV+Z-) or dead  
122 (AV+Z+) (Figure 2C). Neutrophils incubated without GAS remained viable over 180 min (Figure  
123 2D), with 13% exposing PS (Figure 2E) and 3% dead after this time (Figure 2F). In contrast,  
124 incubation of neutrophils with either 5448 or 5448AP resulted in increased PS exposure and cell-  
125 death over 180 min, with significantly more cell-death during 5448 infection compared to  
126 5448AP infection at 30 and 60 min ( $p<0.05$ , Figure 2F). Delay in the initial induction of death in  
127 response to 5448AP suggests extended neutrophil viability during the early stages of infection  
128 (30-60 min).

129 **GAS infection activates caspase-1 in neutrophils**

130 The above data (Figure 2) suggests that GAS induce rapid neutrophil death. To explore the  
131 mechanism of GAS-induced neutrophil death human neutrophil lysates were separated by SDS-  
132 PAGE and screened for the abundance of active caspase-3, caspase-1 and caspase-4 via  
133 immunoblotting and quantified using densitometry (Figures 3A and S2A-D). Cleavage of  
134 executioner caspase-3 to p17 is a definitive hallmark of apoptosis induction (Nicholson et al.,  
135 1995). Conversely, caspase-1 and caspase-4 activity can indicate inflammasome activation, which  
136 in turn can cleave downstream effectors of pyroptosis (Man and Kanneganti, 2016, Sollberger et  
137 al., 2012). Moreover, a recent report has identified the caspase-1 p46 molecule as the principal  
138 active species during inflammasome activation in the cell (Boucher et al., 2018). Neutrophils  
139 incubated in the absence of GAS showed limited evidence of caspase-3 cleavage to p17 (Figures  
140 3A and S2A), while levels of caspase-1 reduced over 180 min (Figures 3A and S2B-C). Infection of  
141 neutrophils with 5448 significantly increased the presence of caspase-3 p17 at 180 min  
142 ( $p>0.0001$ ) compared to both 5448AP-infected and uninfected neutrophils (Figures 3A and S2A).

143 In contrast, incubation of neutrophils with either GAS strain caused an upregulation of caspase-1  
144 (Figures 3A and S2B-C). Compared to uninfected neutrophils, 5448 infection significantly  
145 increased pro-caspase-1 (50kDa) at 30 min, 60 min ( $p<0.05$ ) and 180 min ( $p<0.01$ ), whilst  
146 5448AP infection only significantly increased pro-caspase-1 at 180 min ( $p<0.001$ , Figures 3A and  
147 S2B). Further, 5448 and 5448AP infected neutrophils sustain p46 expression over 180 min,  
148 though this difference was not statistically significant (Figure 3A and S2C). Significant differences  
149 were not seen in the expression of caspase-1 between 5448 and 5448AP infected neutrophils.  
150 Similar to caspase-1, the abundance of full-length caspase-4 in neutrophils incubated in the  
151 absence of GAS declined over time (Figures 3A and S2D). In contrast, 5448 infection increased  
152 caspase-4 expression at 30 ( $p<0.01$ ), 60 ( $p<0.001$ ) and 180 min compared to uninfected  
153 neutrophils ( $p<0.0001$ , Figures 2A and S2D). 5448AP infection however, only increased caspase-  
154 4 expression at 180 min ( $p<0.01$ , Figures 3A and S2D).

155 The above data suggest both GAS strains induce pyroptosis in neutrophils, but the response to  
156 5448AP is delayed. To explore this possibility further, human neutrophils were incubated with  
157 5448, 5448AP or in the absence of GAS, and caspase-1 activity assessed using a fluorogenic flow  
158 cytometric caspase-1 assay (Figures 3B and S3A-C). 5448 infected neutrophils showed increased  
159 active caspase-1 at 60 min and 180 min ( $p<0.05$ ), whilst 5448AP infection increased caspase-1 at  
160 180 min ( $p<0.05$ ) compared to uninfected neutrophils (Figure 3B). No significant differences  
161 were observed between strains although caspase-1 activity was slightly reduced during 5448AP  
162 infection compared to 5448 (Figure 3B), similar to the immunoblot data for caspase-1 p46  
163 (Figures 3A and S2C). Thus, GAS infection of human neutrophils corresponds to increased  
164 caspase-1 activity and caspase-4 expression, consistent with inflammasome activation and  
165 pyroptosis.




166 **Figure 2. GAS infection induced neutrophil death.** Human neutrophils (PMNs) were stained  
167 with Annexin V-FITC and Zombie Aqua Fixable Viability Kit via flow cytometry and initially gated  
168 upon (A) 'Singlets' (FSC-A vs. FSC-H, 10,000 events collected). 'All PMNs' (live and dead) were  
169 selected using (B) a gate excluding GAS. Cells were then compared for fluorescence of (C) annexin  
170 V-FITC/phosphatidylserine (PS) binding against Zombie live/dead viability dye. Purified PMNs  
171 were sampled over 180 min to measure (D) 'Viable' (AV-Z-), (E) 'PS exposed' (AV+Z-), and (F)  
172 'Dead' (AV+Z+), neutrophils during GAS infection (n=3 donors). Results are pooled means $\pm$ SD .  
173 \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001, with black asterisks denoting significance from  
174 control and grey asterisks between 5448 and 5448AP.

175 **Proinflammatory cytokines IL-1 $\beta$  and TNF- $\alpha$  are released by neutrophils in response to  
176 GAS infection**

177 The release of the inflammatory cytokine IL-1 $\beta$  occurs due to caspase-1 activation and is  
178 associated with the induction of pyroptosis (Broz et al., 2010). Uncoordinated release of various  
179 inflammatory cytokines can exacerbate infection (Tecchio et al., 2014). During GAS infection,

180 disease severity is negatively correlated to cytokine concentration (Norrby-Teglund et al., 2000).  
181 Therefore, human neutrophils were incubated with 5448, 5448AP or in the absence of GAS and  
182 supernatants assessed for cytokines using a flow cytometric bead assay. Neutrophils incubated  
183 in the absence of GAS failed to release IL-1 $\beta$  (Figure 3C) and TNF- $\alpha$  (Figure 3D) despite releasing  
184 increasing amounts of IL-8 over 360 min (Figure 3E). Incubation with GAS induced IL-1 $\beta$  release  
185 from neutrophils at 180 min and 360 min, with significantly greater release during 5448AP  
186 infection compared to 5448 at 180 and 360 min ( $p<0.05$ ,  $p<0.0001$ , Figure 3C). Incubation with  
187 GAS also induced significant release of TNF- $\alpha$  from neutrophils at 180 min ( $p<0.001$ ) and 360 min  
188 ( $p<0.0001$ ), with significantly greater release during 5448 infection compared to 5448AP at 360  
189 min ( $p<0.0001$ , Figure 3D). Compared to uninfected neutrophils, 5448 induced significant release  
190 of IL-8 from neutrophils at 60 min and 180 min ( $p<0.05$ ), with significantly greater release than  
191 5448AP at 60 min ( $p<0.05$ , Figure 3E). Neutrophils released minimal amounts of IL-18 over 360  
192 min, and this response did not change following infection with both 5448 or 5448AP (Figure 3F),  
193 suggesting that neutrophils have no major role in IL-18 release over 360 min *in vitro*. These data  
194 indicate that both 5448 and 5448AP induce IL-1 $\beta$  release from human neutrophils, consistent  
195 with the hypothesis that both GAS strains induce pyroptosis in these cells. Moreover, the results  
196 indicate differential cytokine release from human neutrophils infected with GAS, with 5448AP  
197 inducing greater IL-1 $\beta$  release and 5448 inducing greater TNF- $\alpha$  and IL-8 release.




198 **Figure 3. GAS infection activates caspase-1 in human neutrophils and induces**  
199 **proinflammatory cytokine IL-1 $\beta$  and TNF- $\alpha$  release.** (A) Human neutrophil (PMN) lysates  
200 were prepared at 30, 60 and 180 min during GAS infection and compared to uninfected  
201 neutrophils (0, 30, 60, 180 min) via immunoblotting of caspase-3, caspase-1 and caspase-4.  
202 Images shown are from a single donor and are representative of triplicate experiments using  
203 different donors. Immunoblot bands were quantified (ImageJ) and normalised over total protein  
204 (Figure S2). SE=short exposure, LE=long exposure. (B) Caspase-1 activation in human  
205 neutrophils due to GAS infection was confirmed via flow cytometry using FLICA (FAM-YVAD-  
206 FMK) (n=3 donors). Flow cytometry gating strategy used singlets/PMNs (figure S3A-B) and FAM-  
207 FLICA fluorescence (Figure S3C). The release of cytokines from neutrophils during GAS infection  
208 was measured using the LEGENDplex™ human inflammation cytometric bead assay over 360 min.  
209 Neutrophils differentially released (C) IL-1 $\beta$ , (D) TNF- $\alpha$ , (E) IL-8 and (F) IL-18 in response to GAS

210 infection (duplicate measurements, n=6 donors). (B-F) Results are the pooled means $\pm$ SD.  
211 \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001.

212 **GAS infection may cause neutrophil dysfunction**

213 Neutrophil adhesion and activation are central to the innate immune response, with CD11b (Mac-  
214 1) and CD66b (CEACAM8) playing key respective roles (Arnaout, 1990, Power et al., 2001, Skubitz  
215 et al., 1996). CD16 (Fc $\gamma$ RIII) facilitates opsonisation of pathogens and is down-regulated during  
216 apoptosis (Dransfield et al., 1994, Fossati et al., 2002), whilst down-regulation of CD31 (PECAM-  
217 1) facilitates clearance of apoptotic neutrophils and the resolution of inflammation (Brown et al.,  
218 2002, Kurosaka et al., 2003). Therefore, to further explore the impact of GAS on neutrophil  
219 function, human neutrophils were incubated with 5448, 5448AP or in the absence of GAS and the  
220 expression of cell-surface CD11b, CD66b, CD16 and CD31 was assessed using flow cytometry  
221 (Figure 4A-F). In the absence of GAS, neutrophils displayed minor increases in CD11b expression  
222 over time, while incubation with GAS resulted in minor decreases over time, with 5448 inducing  
223 a greater loss of CD11b than 5448AP, though these differences were not statistically significant  
224 (p=0.289, Figure 4C). Neutrophils incubated in the absence of GAS revealed minor increases in  
225 cell-surface CD66b expression over time (Figure 4D). Incubation with GAS further increased  
226 expression of CD66b, with 5448 inducing a slightly greater increase than 5448AP, though these  
227 differences were not statistically significant (p=0.162, Figure 4D). Incubation of neutrophils in  
228 the absence of GAS resulted in a steady decline in CD16 expression over time, a loss significantly  
229 increased by co-incubation with either GAS strain 180 min post-infection (p<0.0001, Figure 4E).  
230 Notably, incubation of neutrophils with 5448 induced a significantly greater loss of CD16  
231 expression than 5448AP incubation at all earlier time points (Figure 4E). Similar to CD16,  
232 incubation of neutrophils in the absence of GAS resulted in a steady decline in CD31 expression  
233 over time, a loss significantly increased by co-incubation with either GAS strain 180 min post-  
234 infection (p<0.0001, Figure 4F). Moreover, incubation of neutrophils with 5448 induced a  
235 significantly greater loss of CD31 expression than 5448AP incubation at earlier time points.

236 Collectively, these data indicate that GAS has minimal impact upon human neutrophil CD11b and  
237 CD66b, but increases the loss of CD16 and CD31 expression, which may impact opsonisation of  
238 GAS and subsequent efferocytosis of neutrophils by macrophages, during infection.



239 **Figure 4. GAS infection changes neutrophil functionality.** Human neutrophils (PMNs) were  
240 analysed using flow cytometry, sequentially gated upon (A) 'Singlets' (FSC-A vs. FSC-H, 10,000  
241 events collected) then (B) viable 'PMNs' (FSC-A vs. FSC-H). Purified neutrophils infected with GAS  
242 were sampled over 180 min for the cell-surface expression of (C) CD11b-FITC (n=4 donors), (D)  
243 CD66b-PerCP/Cy5.5 (n=5 donors), (E) CD16-FITC (n=4 donors) and (F) CD31-PE/Cy7 (n=4  
244 donors). Results are the pooled means $\pm$ SD. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and \*\*\*\*p<0.0001, with  
245 black asterisks denoting significance from control and grey asterisks between 5448 and 5448AP.

#### 246 **GAS infection activates caspase-1 in neutrophils *in vivo***


247 The above data indicate that GAS influences human neutrophils *in vitro*. To explore if GAS may  
248 alter neutrophils *in vivo*, we assessed the neutrophil response in a mouse model of GAS infection  
249 (Ly et al., 2014, Maamary et al., 2010, Tsatsaronis et al., 2014). C57BL/6J mice were injected  
250 intradermally with 5448, 5448AP or saline and euthanised at 6 or 24 hours post infection, with  
251 neutrophil populations (CD45+/CD11b+/Ly-6G+), caspase-1 activation and CD16 expression

252 characterised by flow cytometry (Figures 5A-C, 5E and S4A-F). Infection of mice with either GAS  
253 strain significantly increased neutrophil populations at sites of injection at both 6 and 24 h  
254 compared to saline control ( $p<0.001$ , Figure 5A). The percentage of circulating neutrophils in the  
255 blood at 6 h significantly increased during infection with both GAS strains ( $p<0.01$ ), though the  
256 response to 5448AP was significantly greater than 5448 ( $p<0.05$ , Figure 5B). Blood neutrophil  
257 populations returned to baseline after 24 h, indicating the importance of neutrophils during the  
258 early stages of infection (Figure 5B). Murine neutrophils lavaged from sites of saline injection had  
259 low amounts of active caspase-1 (Figure 5B). Infection with 5448AP, but not 5448, significantly  
260 increased caspase-1 activation at 6 h ( $p<0.05$ ), while both strains increased caspase-1 activation  
261 at 24 h ( $p<0.001$ , Figure 5C). Cytokines were assessed in murine serum using a flow cytometric  
262 bead assay. IL-1 $\beta$  concentrations remained low for saline control and 5448 infected mice but  
263 were significantly increased at 24 h during 5448AP infection ( $p<0.0001$ , Figure 5D). Neutrophils  
264 lavaged from the site of saline and GAS injection displayed CD16 expression, with CD16  
265 expression significantly increased due to 5448 but not 5448AP infection at 6 h when compared  
266 to saline control ( $p<0.05$ , Figure 5E). The expression of CD16 on neutrophils from mice infected  
267 with 5448 significantly decreased between 6 and 24 h ( $p<0.01$ ), but no significant differences  
268 were noted between times for either saline or 5448AP groups (Figure 5E).

269 **Discussion**

270 Here we have mapped the human neutrophil response to GAS, addressing cell-death, signalling  
271 and the inflammatory profile during the early stages of M1T1 (5448 and 5448AP) infection, while  
272 also confirming *in vitro* findings in a murine intradermal GAS infection model. For the first time,  
273 we describe an inflammatory neutrophil phenotype, as evidenced by caspase-1 activation *in vitro*  
274 and *in vivo*, that may promote inflammation and exacerbate GAS disease. Most notably, changes  
275 to the expression of cell-surface proteins CD16 and CD31 may impede the removal of bacteria and  
276 clearance of neutrophils at sites of infection, hindering the resolution of inflammation. Further,

277 we elucidate differences between 5448 and 5448AP that aid in understanding the survival and  
278 proliferation of GAS harbouring *covS* mutations in the presence of human neutrophils.



279 **Figure 5. GAS infection *in vivo* activates caspase-1 in murine neutrophils.** Percentage of  
280 CD45 $^{+}$  cells (A) lavaged from site of injection and in (B) circulating blood characterised as  
281 neutrophils (PMNs, CD11b $^{+}$ /Ly-6G $^{+}$ ) by flow cytometry (Figure S4A-E). (C) Caspase-1 activation  
282 in neutrophils at site of GAS infection was confirmed via flow cytometry using FLICA 660 (660-  
283 YVAD-FMK, Figure S4F). Each data point represents the results from a single mouse where n=8.  
284 (D) The release of IL-1 $\beta$  in mouse serum during GAS infection was measured using the  
285 LEGENDplex<sup>TM</sup> mouse inflammation cytometric bead assay at 6 and 24 h post infection where  
286 duplicate measurements are shown and n=8. (E) CD16 expression of PMNs lavaged from the site  
287 of injection and determined using flow cytometry. Each data point represents the results from a  
288 single mouse where n=8. Results are the means $\pm$ SD. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 and  
289 \*\*\*\*p<0.0001, with black asterisks denoting significance from control and grey asterisks between  
290 5448 and 5448AP, or as indicated by a line.

291 The temporal expression of neutrophil cell surface markers has not previously been investigated  
292 in the context of GAS infection. Our data show that significant reductions to both CD16 and CD31  
293 occur in neutrophils due to GAS infection *in vitro*. Additionally, *in vivo* data indicates that a  
294 reduction in CD16 expression is seen during 5448 infection between 6 and 24 h. CD16 functions  
295 as a receptor for opsonised bacteria and immune complexes (Fossati et al., 2002), whilst the loss  
296 of CD16 has also been associated with the induction of apoptosis (Dransfield et al., 1994). The  
297 induction of apoptosis following bacterial phagocytosis is advantageous to the host as it promotes  
298 controlled removal of bacteria and the resolution of inflammation (Kobayashi et al., 2018). We  
299 hypothesise that the retention of CD16 during infection promotes a reduction in apoptosis and  
300 prolonged degranulation at the site of infection. Further, CD31 expression is reduced during GAS  
301 infection, facilitating the eventual removal of neutrophils from sites of infection (Kobayashi et al.,  
302 2003). Parallel to CD16, CD31 is retained during 5448AP infection of neutrophils to a greater  
303 extent than 5448 infection *in vitro*. This may result in neutrophils remaining at sites of infection  
304 longer, further increasing inflammation. Additionally, we report a trend towards increased cell-  
305 surface expression of CD11b and CD66b during GAS infection. Migration of neutrophils to sites of  
306 infection, facilitated by CD11b-mediated neutrophil adhesion (Arnaout, 1990), may therefore be  
307 affected during GAS infection. Down-regulation of CD11b can prevent accumulation of  
308 neutrophils at inflammatory sites (Huston et al., 2009), however retention, such as that seen  
309 during 5448AP infection may contribute to prolonged inflammation. Neutrophil activation can be  
310 determined through the expression of cell-surface CD66b following stimulation (Skubitz et al.,  
311 1996). Reduced cell-surface CD66b expression in response to 5448AP infection may therefore  
312 indicate a reduction to neutrophil function and further explain the resistance to neutrophil-  
313 mediated killing. Collectively, the neutrophil response is altered and inflammation prolonged at  
314 sites of *covS* mutant GAS infection.

315 Disruption of the role neutrophils play during the resolution of GAS infection and induction of  
316 inflammatory death pathways has been reported previously (Kobayashi et al., 2003, Tsatsaronis  
317 et al., 2015). Proinflammatory activation of the NLRP3 inflammasome in macrophages has been

318 demonstrated for M1 GAS (Valderrama et al., 2017), here we provide the first evidence that GAS  
319 activates caspase-1 in human and murine neutrophils, consistent with inflammasome activation  
320 and pyroptosis. Caspase-1 activation was consistent during infection with both M1T1 GAS  
321 isolates, however the release of inflammatory cytokine IL-1 $\beta$ , a hallmark of clinical invasive  
322 infection (LaRock and Nizet, 2015), was only significantly increased in response to 5448AP  
323 infection *in vitro* and *in vivo*. In murine bone marrow-derived dendritic cells caspase-1 activation  
324 is essential for IL-1 $\beta$  release (Schneider et al., 2017). The activation of caspase-1 in human and  
325 murine neutrophils does not correlate directly to the amount of IL-1 $\beta$  released, and an alternative  
326 mechanism may facilitate IL-1 $\beta$  maturation. Type I interferons are known regulators of IL-1 $\beta$  in  
327 GAS infected mice (Castiglia et al., 2016), where increased IL-1 $\beta$  release in murine serum seen in  
328 this study may also be attributed to disruption of this homeostatic relationship. Increased IL-1 $\beta$ ,  
329 being a neutrophil chemoattractant, therefore may further promote inflammation at sites of  
330 infection following release (Chen et al., 2007), supporting the hypothesis that *covS* mutant GAS  
331 promote greater levels of inflammation during GAS infection.

332 Previous studies have characterised differences between 5448 and 5448AP, demonstrating  
333 resistance to neutrophil-mediated killing *in vitro* and increased bacterial dissemination and  
334 decreased survival *in vivo* following the acquisition of *covS* mutations (Fiebig et al., 2015,  
335 Maamary et al., 2010, Walker et al., 2007). Here, we demonstrate that 5448AP is not only resistant  
336 to neutrophil-mediated killing but proliferates in the presence of functional neutrophils. GAS  
337 survival has been demonstrated intracellularly in murine neutrophils and human macrophages  
338 (Medina et al., 2003a, Medina et al., 2003b, O'Neill et al., 2016) and can even be facilitated by host  
339 red blood cells (Wierzbicki et al., 2019). Increased 5448AP proliferation may result from the  
340 reduction in neutrophil ROS response during infection. GAS has previously been shown to display  
341 resistance to ROS through numerous virulence mechanisms (Henningham et al., 2015). The  
342 absence of a hostile environment may further permit bacterial replication. Additionally, the  
343 increased production of ROS can induce neutrophil death via apoptosis (Geering and Simon,  
344 2011). Reduced neutrophil ROS production during 5448AP infection may therefore explain the

345 reduction seen in caspase-3 activation (apoptosis). Previously it has been demonstrated that GAS  
346 M1 strain MGAS5005 modulates neutrophil apoptosis (Kobayashi et al., 2003), a finding which is  
347 supported by the current study.

348 Changes to the function of neutrophils during the initial innate immune response have the  
349 potential to hinder mechanisms essential for the resolution of infection. Disruption to these  
350 processes during GAS infection may induce this neutrophil phenotype we have described, with  
351 increased inflammatory properties and potential to exacerbate infection. Caspase-1 activation  
352 during GAS infection of neutrophils indicates possible inflammasome activation and death via  
353 pyroptosis. Further studies should explore the precise cell death mechanism. A reduction in  
354 apoptosis is evident during *covS* GAS infection, as has been reported for non-M1T1 GAS  
355 (Tsatsaronis et al., 2015), whilst modulation of apoptosis has previously been implicated as a  
356 factor contributing to GAS survival (Kobayashi et al., 2003). The current study aids in  
357 understanding the complex host-pathogen interaction identifying host factors that may  
358 contribute to severe pathology of invasive GAS infection. Future studies may be able to isolate  
359 host-specific targets that could be exploited to control inflammation and tissue damage during  
360 invasive GAS infection.

361 **Acknowledgements**

362 We thank Professor Marijka Batterham (University of Wollongong) for her statistical  
363 consultation. We thank Associate Professor Thomas Proft (University of Auckland, New Zealand)  
364 for pLZ12Km2-P23R:TA. We also thank our generous blood donors for their participation and  
365 time.

366 **Author Contributions**

367 Conceptualisation, M.S.S., R.S., J.A.T., J.G.W.; Methodology, M.S.S., R.S., J.G.W., J.G., J.D.M., D.L.;  
368 Investigation, J.G.W., D.L., N.J.G., H.K.N.V.; Data and figure curation, J.G.W., D.L., R.S., M.S.S.; Writing-  
369 Original draft, J.G.W.; Writing-Review and editing, M.S.S., R.S., J.G.W., D.L., N.J.G., J.D.M., H.K.N.V.,

370 J.G., J.A.T.; Funding acquisition, M.S.S and D.L.; Resources, M.S.S., J.D.M.; Supervision, M.S.S., R.S.,  
371 J.G.

372 **Declaration of Interests**

373 The authors declare no competing interests.

374 **Materials and Methods**

375 **Ethics statement**

376 All experiments involving the use of human blood were conducted with informed consent of  
377 healthy volunteers, approved and authorised by the University of Wollongong Human Research  
378 Ethics Committee (Protocol HE08/250). All experiments involving the use of animals were  
379 approved and authorised by the University of Wollongong Animal Ethics Committee (Protocol  
380 AE18/10).

381 **Bacterial strains and culture**

382 *Escherichia coli* MC106 were grown in Luria–Bertani Broth (LB) at 37 °C with constant shaking.  
383 M1T1 *S. pyogenes* invasive clinical isolate 5448 (*emm1*) and hypervirulent animal passaged  
384 5448AP (containing a non-functional control of virulence regulator mutation) have been  
385 described previously (Aziz et al., 2004, Chatellier et al., 2000). GAS strains were routinely cultured  
386 at 37°C on horse-blood agar (Thermo Fisher) and enumerated on yeast supplemented (1% w/v)  
387 Todd–Hewitt (THY, Benton Dickson) agar. Static overnight cultures were grown at 37°C in THY  
388 then sub-inoculated (1:10) into fresh THY and grown to mid-logarithmic phase, antibiotics were  
389 added when required (100 µg/ml ampicillin and 200 µg/ml kanamycin). Bacterial pellets were  
390 washed twice with phosphate buffered saline (PBS) then resuspended at the specified  
391 multiplicity of infection (MOI) and assay specific media conditions.

392 **Construction of GFP expression vector pLZ12Km2-P23R-TA:GFP for GAS**

393 In brief, stable GFP expression by GAS was created by synthesizing the ribosomal binding site  
394 (RBS) and *gfp* gene from pDCerm-GFP (Ly et al., 2014) into the pUC57 plasmid (GenScript),  
395 resulting in pUC57-RBSGFP plasmid. RBS and *gfp* from pUC57-RBSGFP were then sub-cloned  
396 using NotI into the toxin-antitoxin (TA) stabilized expression plasmid pLZ12Km2-P23R:TA,  
397 kindly provided by Associate Professor Thomas Proft (University of Auckland, New Zealand) (Loh  
398 and Proft, 2013), to produce pLZ12Km2-P23R-TA:GFP. The resultant plasmid system utilises the  
399 *Streptococcal*  $\omega$ - $\epsilon$ - $\zeta$  TA cassette to achieve segregational plasmid stability under non-selective  
400 conditions (Lioy et al., 2010).

401 Specifically, plasmids pLZ12Km2-P23R:TA and pUC57-RBSGFP (engineered with RBS and *gfp*  
402 from pDCerm-GFP) were first transformed into chemically competent *E. coli* MC106 via  
403 electroporation. The plasmids were then retrieved and purified from *E. coli* cultures using a  
404 Wizard® Plus SV Minipreps DNA Purification System (Promega). The pLZ12Km2-P23R:TA  
405 plasmid was digested with 20 U NotI enzyme and further treated with 5 U shrimp alkaline  
406 phosphatase. The pUC57-RBSGFP plasmid was also incubated with 20 U NotI to excise the RBS  
407 and *gfp* gene from pUC57-RBSGFP, and these were then ligated into digested pLZ12Km2-P23R:TA  
408 plasmid. The resulting plasmid, pLZ12Km2-P23R-TA:GFP, was then transformed and cloned in  
409 MC106 *E. coli*, and later extracted and purified. pLZ12Km2-P23R-TA:GFP was transformed into  
410 GAS using standard GAS electroporation techniques (McLaughlin and Ferretti, 1995).  
411 Transformed GAS was confirmed for GFP expression via flow cytometry.

#### 412 **Isolation of human neutrophils**

413 Venous human blood was drawn into 10 mL lithium heparin-coated Vacutainer (Benton Dickson)  
414 tubes and layered over equal volumes of Polymorphprep (Axis Shield) and centrifuged as per  
415 manufacturer's instructions. The resulting layer of neutrophils was isolated and erythrocytes  
416 hypotonically lysed. Isotonic concentration was restored with Hank's Balanced Salt solution  
417 (without  $\text{Ca}^{2+}$  or  $\text{Mg}^{2+}$ , Corning Inc.). Prior to experimentation neutrophils were resuspended at  
418 specified concentrations in complete medium, Roswell Park Memorial Institute (RPMI)-1640

419 medium (Life Technologies) containing 2% heat-inactivated autologous plasma and 2 mM L-  
420 glutamine (Life Technologies), unless otherwise stated. Neutrophil viability was assessed via  
421 Trypan Blue (Sigma-Aldrich) staining and neutrophil purity was assessed using a Benton Dickson  
422 LSR Fortessa X-20 flow cytometer via distinct forward and side scatter profiles or CD66b-  
423 peridinin chlorophyll protein (PerCP)/Cy5.5 (clone G10F5, BioLegend) expression. Neutrophils  
424 were maintained at room temperature throughout processing.

425 ***In vitro* infection of neutrophils with GAS**

426 Purified human neutrophils were seeded in either 96-well plates at MOI (GAS:neutrophil) 1:10  
427 (survival and proliferation) or 10:1 (ROS production and cytokine release), 24-well plates at 10:1  
428 (phagocytosis, Annexin-V/Viability staining, CD expression and FAM-FLICA caspase-1 activation)  
429 or 6-well plates at 10:1 (immunoblotting) and incubated at 37°C in 5% CO<sub>2</sub>.

430 **GAS survival and proliferation**

431 Human neutrophils were co-cultured with GAS or lysed via three freeze-thaw cycles prior to  
432 incubation. To block phagocytosis neutrophils were preincubated with 10 µM cytochalasin D  
433 (Cayman Chemicals) in complete medium at 37°C for 30 min prior to infection. At indicated time  
434 points neutrophils were hypotonically lysed and surviving bacteria serially diluted before plating  
435 on THY agar.

436 **GAS phagocytosis**

437 Human neutrophils were co-cultured with GAS expressing GFP for the times indicated in  
438 complete medium. Cells were removed and washed twice with 10% (v/v) heat-inactivated foetal  
439 bovine serum (FBS, Bovogen Biologicals) diluted in PBS, followed by data acquisition via flow  
440 cytometry.

441 **ROS production**

442 ROS production was assessed as previously described (Kobayashi et al., 2003). Briefly, prior to  
443 infection, human neutrophils were incubated in complete medium containing 25  $\mu$ M  
444 dichlorofluorescein (DCF, Molecular Probes) for 45 min at room temperature (RT). ROS  
445 production was measured fluorometrically ( $_{\text{ex}}485$  nm  $_{\text{em}}520$  nm) using a POLARstar Omega plate  
446 reader (BMG Labtech).

447 **Flow cytometry**

448 For human neutrophil in vitro assays, flow cytometry data was acquired using a BD LSR Fortessa  
449 X-20 with excitation lasers; violet (405 nm), blue (488 nm), yellow/green (561 nm) and red (640  
450 nm). Bandpass filters for Zombie Aqua Fixable Viability Kit (525/50), fluorescein isothiocyanate  
451 (FITC)/GFP/FAM FLICA (525/50), PerCP-Cy5.5 (695/40) R-phycoerythrin (PE, 586/15),  
452 propidium iodide (PI, 610/20), PE-Cy7 (780/60) and allophycocyanin (APC, 670/30) were used.  
453 For murine infection studies, flow cytometry data was acquired using an Invitrogen Attune NxT  
454 with excitation lasers; violet (405 nm), blue (488 nm), yellow (561 nm) and red (638 nm).  
455 Bandpass filters VL1 (440/50), VL2 (512/25), BL1 (530/30), YL1 (585/16), YL3 (695/40) and  
456 RL2 (720/30) were used. Data was analysed using FlowJo software V10.6.1 (TreeStar Inc.).

457 **Annexin-V/viability staining**

458 To assess cell viability human neutrophils at indicated times were washed with PBS and  
459 incubated with Zombie Aqua Fixable Viability Kit (BioLegend) for 15 min at RT. Cells were  
460 washed again once with PBS, then 10% (v/v) FBS in PBS and stained with Annexin-V-FTIC  
461 (BioLegend) for 15 min at RT. Cells were analysed immediately via flow cytometry.

462 **Immunoblotting and antibodies**

463 Following co-culture in the presence or absence of GAS, human neutrophil lysates were prepared  
464 in RIPA buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, 1.0% (v/v) Triton X-100, 0.1% (w/v) SDS,  
465 0.5% (w/v) sodium deoxycholate, 2x complete protease inhibitor cocktail (Roche), 1 mM  
466 phenylmethylsulphonyl fluoride, 5 mM sodium pyrophosphate, 5 mM sodium molybdate and 5

467 mM  $\beta$ -glycerophosphate) following co-culture in the presence or absence of GAS and incubated  
468 for 30 min on ice with intermittent vortexing. Soluble fractions were separated via centrifugation  
469 at 4°C, snap frozen in liquid N<sub>2</sub> and stored at -80°C. Protein concentrations were determined by  
470 comparison to bovine serum albumin standards using the DC Protein Assay (Bio-Rad) and  
471 absorbance (A<sub>750nm</sub>) measured using a POLARstar Omega plate reader. Neutrophil lysates (20  $\mu$ g)  
472 were separated on 4-20% TGX Stain-Free protein gels (Bio-Rad) as per the manufacturer's  
473 running conditions then activated for 5 min under UV to determine total protein (Bio-Rad  
474 ChemiDoc XR, Image Lab Software). Proteins were transferred to PVDF membranes (Bio-Rad),  
475 blocked, then incubated overnight at 4°C with caspase-1 polyclonal (1:1000, #2225), caspase-3  
476 polyclonal (1:1000, #9662), caspase-4 polyclonal (1:1000, #4450) or caspase-8 monoclonal  
477 (1:1000, #4790) antibodies (Cell Signalling Technology). PVDF membranes were washed thrice  
478 between incubations for 5 min with tris-buffered saline containing 0.1% (v/v) Tween 20. PVDF  
479 membranes were incubated with horseradish peroxidase-conjugated goat $\times$ rabbit IgG (1:5000,  
480 Invitrogen) for 1 h at RT and detected using Clarity or Clarity Max Western ECL Blotting Substrate  
481 (Bio-Rad) and imaged (Amersham AI600). Bands were quantified using ImageJ software  
482 (National Institutes of Health) as area under the peak and normalised over UV determined total  
483 protein.

484 **FAM-FLICA caspase-1 activation**

485 Caspase-1 activation was measured using FAM-FLICA Caspase-1 assay kit (ImmunoChemistry  
486 Technologies) as per the manufacturer's instructions. In brief, following co-culture of human  
487 neutrophils with GAS, cells were removed and incubated in serum free medium (RPMI-1640)  
488 containing 1 x FAM-YVAD-FMK for 60 min at 37°C. Cells were then analysed for caspase-1  
489 activation via flow cytometry.

490 **Cytometric cytokine bead assay**

491 Human neutrophil supernatants were at indicated times during GAS infection, snap frozen with  
492 liquid N<sub>2</sub> and stored at -80°C for a period no longer than 5 days. Neutrophils were assessed for  
493 the release of cytokines IL-1 $\beta$ , IL-8, IL-18 and TNF- $\alpha$  using the LEGENDplex™ human  
494 inflammation panel bead-based immunoassay (BioLegend) and flow cytometry as per  
495 manufacturer's instructions. In brief, samples and standards were incubated with beads and  
496 detection antibodies for 120 min at room temperature, with shaking (600 rpm) protected from  
497 light. PE-conjugated streptavidin was then added and incubated for a further 30 min at room  
498 temperature, with shaking (600 rpm) protected from light. Beads were washed twice with  
499 LEGENDplex™ wash buffer and data collected via flow cytometry. Beads were initially gated upon  
500 FSC-A and SSC-A (A and B populations). Cytokines have signature APC fluorescence with  
501 quantitative expression determined using PE fluorescence in comparison to cytokine standards.  
502 Data was analysed using the LEGENDplex™ software V8.0 (VigeneTech Inc.).

503 **Cluster of differentiation expression**

504 Human neutrophil cell surface CD expression was assessed during GAS infection. Neutrophils at  
505 indicated times were washed with PBS then routinely incubated with Zombie Aqua Fixable  
506 Viability Kit for 15 min at RT. Cells were washed once again in PBS, followed by 10% (v/v) FBS in  
507 PBS. Neutrophils were stained with fluorochrome-conjugated antibodies CD11b-FITC (Clone  
508 ICRF44), CD31-PE/Cy7 (Clone WM59), or CD66b-PerCP/Cy5.5 (Clone G10F5) (BioLegend) and  
509 CD16-FITC (Clone 3G8, Benton Dickson) for 15 min at RT. Neutrophils were washed with 10%  
510 (v/v) FBS in PBS then analysed via flow cytometry.

511 **Murine intradermal GAS infection model**

512 Intradermal GAS challenge of C57BL/6J mice has been described previously (Ly et al., 2014,  
513 Maamary et al., 2010, Tsatsaronis et al., 2014). In brief, equal numbers of 6-8 week old male and  
514 female C57BL/6J mice (Australian BioResources) were anaesthetised via isoflurane inhalation,  
515 followed by two intradermal injections into shaved left and right flanks with either 1 x 10<sup>8</sup> CFU  
516 of mid-logarithmic GAS or 100  $\mu$ L sterile 0.7% saline. Mice were euthanised via slow-fill CO<sub>2</sub>

517 asphyxiation at 6 or 24 h post-infection. Blood collected via cardiac puncture was separated into  
518 two aliquots for serum and flow cytometric analysis. Serum was collected by clotting for 1 h at RT  
519 then placed on ice until centrifugation at 1200 x g for 10 min at 4°C, then immediately stored at -  
520 80°C until use. Remaining blood samples were mixed with 20 µL 0.5% sodium citrate (w/v) per  
521 mL of blood and placed on ice. Equal volume of PBS was added to the blood sample and  
522 centrifuged at 350 x g for 5 min. For erythrocyte lysis, samples were incubated with 1 mL of  
523 ammonium-chloride-potassium lysing buffer (150 mM NH<sub>4</sub>Cl, 1 mM KHCO<sub>3</sub>, 0.1 mM Na<sub>2</sub>CO<sub>3</sub>, pH  
524 7.3) for 5 min with gentle agitation and centrifuged at 350 x g for 5 min. This process was repeated  
525 and cells were then washed with PBS and resuspended in 500 µL PBS and placed on ice.  
526 Additionally, sites of infection were lavaged with 1 mL of sterile 0.7% saline, and fluid collected  
527 from both right and left flanks was pooled to increase cell numbers. Pooled samples were kept  
528 cold until centrifugation at 350 x G for 5 min, resuspended in 500 µL of PBS and placed on ice.  
529 Both blood and lavage fluid samples were analysed via flow cytometry.

530 **Flow cytometric analysis of murine cells**

531 Cell viability was assessed as described above. To assess caspase-1 activation and CD expression,  
532 cells were initially washed with 1 mL of PBS, followed by 1 mL of 10% (v/v) FBS in PBS. Cells  
533 were then centrifuged and simultaneously stained with 1 x 660-YVAD-FMK (FLICA 660 Caspase-  
534 1 assay kit, ImmunoChemistry Technologies) for caspase-1 activation and with fluorochrome-  
535 conjugated antibodies CD45-BV421 (clone 30-F11), CD11b-PE/Cy5 (clone M1-70) and Ly-6G-PE  
536 (clone 1A8) (Biolegend) and CD16-FITC (clone AT154-2, Bio-Rad) in RPMI 1640 media for 30 min  
537 at RT . Cells were washed with 10% (v/v) FBS in PBS and analysed via flow cytometry.

538 **Murine serum IL-1 $\beta$  concentration**

539 IL-1 $\beta$  release was measured in murine serum using the LEGENDplex™ mouse inflammation panel  
540 bead-based immunoassay (BioLegend) and flow cytometry as described above except shaking  
541 was performed at 800 rpm.

542 **Statistical analyses**

543 Graphs were created using Prism 6 (GraphPad Software Inc.) and statistical analysis was  
544 performed using Prism 6 and IBM SPSS Statistics 25 (IBM® corporation). Data was analysed  
545 using one-way and two-way ANOVA to determine significant differences and adjusted using  
546 Tukey HSD corrections or as stated otherwise. To account for the nested nature of the human  
547 neutrophil Annexin-V/Zombie and CD data with repeated measures over time in the same donor,  
548 a linear mixed model was used to determine significant interaction between treatment and time.  
549 Post-hoc tests were performed by multiple one-way ANOVA at each time point where multiple  
550 comparisons were adjusted using Tukey HSD corrections. *In vivo* data was analysed by two-way  
551 ANOVA where differences are shown between treatment and time, also using Tukey HSD  
552 corrections. Values presented for 'p' represent interaction (treatment\*time) unless otherwise  
553 stated. \* p<0.05; \*\* p<0.01; \*\*\* p<0.001; \*\*\*\* p<0.0001.

554 **References**

555 Arnaout, M. A. 1990. Structure and function of the leukocyte adhesion molecule CD11/CD18. *Blood*,  
556 75, 1037-1050.

557 Ato, M., Ikebe, T., Kawabata, H., Takemori, T. & Watanabe, H. 2008. Incompetence of neutrophils to  
558 invasive group A streptococcus is attributed to induction of plural virulence factors by  
559 dysfunction of a regulator. *PLoS ONE*, 3.

560 Aziz, R. K. & Kotb, M. 2008. Rise and persistence of global M1T1 clone of Streptococcus pyogenes.  
561 *Emerging Infectious Diseases*, 14, 1511-1517.

562 Aziz, R. K., Pabst, M. J., Jeng, A., Kansal, R., Low, D. E., Nizet, V. & Kotb, M. 2004. Invasive M1T1  
563 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of  
564 multiple virulence factors by SpeB. *Molecular Microbiology*, 51, 123-134.

565 Boucher, D., Monteleone, M., Coll, R. C., Chen, K. W., Ross, C. M., Teo, J. L., Gomez, G. A., Holley, C.  
566 L., Bierschenk, D., Stacey, K. J., Yap, A. S., Bezbradica, J. S. & Schroder, K. 2018. Caspase-1  
567 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. *Journal of  
568 Experimental Medicine*, 215, 827-840.

569 Bratton, D. L. & Henson, P. M. 2011. Neutrophil clearance: When the party is over, clean-up begins.  
570 *Trends in Immunology*, 32, 350-357.

571 Brown, K., Brain, S., Pearson, J., Edgeworth, J., Lewis, S. & Treacher, D. 2006. Neutrophils in  
572 development of multiple organ failure in sepsis. *Lancet*, 368, 157-169.

573 Brown, S., Heinisch, I., Ross, E., Shaw, K., Buckley, C. O. & Savill, J. 2002. Apoptosis disables CD31-  
574 mediated cell detachment from phagocytes promoting binding and engulfment. *Nature*, 418,  
575 200-203.

576 Broz, P., Von Moltke, J., Jones, J. W., Vance, R. E. & Monack, D. M. 2010. Differential requirement for  
577 caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. *Cell Host and Microbe*, 8, 471-483.

579 Castiglia, V., Piersigilli, A., Ebner, F., Janos, M., Goldmann, O., Damböck, U., Kröger, A., Weiss, S.,  
580 Knapp, S., Jamieson, A. M., Kirschning, C., Kalinke, U., Strobl, B., Müller, M., Stoiber, D.,  
581 Lienenklaus, S. & Kovarik, P. 2016. Type I Interferon Signaling Prevents IL-1 $\beta$ -Driven Lethal  
582 Systemic Hyperinflammation during Invasive Bacterial Infection of Soft Tissue. *Cell Host and*  
583 *Microbe*, 19, 375-387.

584 Chatellier, S., Ihendyane, N., Kansal, R. G., Khambaty, F., Basma, H., Norrby-Teglund, A., Low, D. E.,  
585 Mcgeer, A. & Kotb, M. 2000. Genetic relatedness and superantigen expression in group A  
586 streptococcus serotype M1 isolates from patients with severe and nonsevere invasive  
587 diseases. *Infection and Immunity*, 68, 3523-3534.

588 Chen, C. J., Kono, H., Golenbock, D., Reed, G., Akira, S. & Rock, K. L. 2007. Identification of a key  
589 pathway required for the sterile inflammatory response triggered by dying cells. *Nature*  
590 *Medicine*, 13, 851-856.

591 Cole, J. N., Barnett, T. C., Nizet, V. & Walker, M. J. 2011. Molecular insight into invasive group A  
592 streptococcal disease. *Nature Reviews Microbiology*, 9, 724-736.

593 Davies, H. D., Mcgeer, A., Schwartz, B., Green, K., Cann, D., Simor, A. E. & Low, D. E. 1996. Invasive  
594 group A streptococcal infections in Ontario, Canada. *New England Journal of Medicine*, 335,  
595 547-554.

596 Dransfield, I., Buckle, A. M., Savill, J. S., Mcdowall, A., Haslett, C. & Hogg, N. 1994. Neutrophil  
597 apoptosis is associated with a reduction in CD16 (Fc $\gamma$ RIII) expression. *Journal of Immunology*,  
598 153, 1254-1263.

599 Edwards, R. J., Pyzio, M., Gierula, M., Turner, C. E., Abdul-Salam, V. B. & Sriskandan, S. 2018.  
600 Proteomic analysis at the sites of clinical infection with invasive Streptococcus pyogenes.  
601 *Scientific Reports*, 8.

602 Epstein, F. H. & Weiss, S. J. 1989. Tissue Destruction by Neutrophils. *New England Journal of*  
603 *Medicine*, 320, 365-376.

604 Faurschou, M. & Borregaard, N. 2003. Neutrophil granules and secretory vesicles in inflammation.  
605 *Microbes and Infection*, 5, 1317-1327.

606 Fiebig, A., Loof, T. G., Babbar, A., Itzek, A., Koehorst, J. J., Schaap, P. J. & Nitsche-Schmitz, D. P. 2015.  
607 Comparative Genomics of Streptococcus pyogenes M1 isolates differing in virulence and  
608 propensity to cause systemic infection in mice. *International Journal of Medical*  
609 *Microbiology*, 305, 532-543.

610 Fossati, G., Moots, R. J., Bucknall, R. C. & Edwards, S. W. 2002. Differential role of neutrophil Fc $\gamma$   
611 receptor IIb (CD16) in phagocytosis, bacterial killing, and responses to immune complexes.  
612 *Arthritis and Rheumatism*, 46, 1351-1361.

613 Geering, B. & Simon, H. U. 2011. Peculiarities of cell death mechanisms in neutrophils. *Cell Death*  
614 *and Differentiation*, 18, 1457-1469.

615 Ghimire, L., Paudel, S., Jin, L., Baral, P., Cai, S. & Jeyaseelan, S. 2018. NLRP6 negatively regulates  
616 pulmonary host defense in Gram-positive bacterial infection through modulating neutrophil  
617 recruitment and function. *PLoS Pathogens*, 14.

618 Greenlee-Wacker, M. C., Kremserová, S. & Nauseef, W. M. 2017. Lysis of human neutrophils by  
619 community-associated methicillin-resistant *Staphylococcus aureus*. *Blood*, 129, 3237-3244.

620 Henningham, A., Döhrmann, S., Nizet, V. & Cole, J. N. 2015. Mechanisms of group A Streptococcus  
621 resistance to reactive oxygen species. *FEMS Microbiology Reviews*, 39, 488-508.

622 Huston, J. M., Rosas-Ballina, M., Xue, X., Dowling, O., Ochani, K., Ochani, M., Yeboah, M. M.,  
623 Chatterjee, P. K., Tracey, K. J. & Metz, C. N. 2009. Cholinergic neural signals to the spleen  
624 down-regulate leukocyte trafficking via CD11b. *Journal of Immunology*, 183, 552-559.

625 Kilsgård, O., Karlsson, C., Malmström, E. & Malmström, J. 2016. Differential compartmentalization of  
626 Streptococcus pyogenes virulence factors and host protein binding properties as a  
627 mechanism for host adaptation. *International Journal of Medical Microbiology*.

628 Kipnis, E. 2013. Neutrophils in sepsis: Battle of the bands. *Critical Care Medicine*, 41, 925-926.

629 Kobayashi, S. D., Braughton, K. R., Whitney, A. R., Voyich, J. M., Schwan, T. G., Musser, J. M. & Deleo,  
630 F. R. 2003. Bacterial pathogens modulate an apoptosis differentiation program in human  
631 neutrophils. *Proceedings of the National Academy of Sciences of the United States of*  
632 *America*, 100, 10948-10953.

633 Kobayashi, S. D., Malachowa, N. & Deleo, F. R. 2018. Neutrophils and Bacterial Immune Evasion.  
634 *Journal of Innate Immunity*, 10, 432-441.

635 Kovach, M. A. & Standiford, T. J. 2012. The function of neutrophils in sepsis. *Current Opinion in*  
636 *Infectious Diseases*, 25, 321-327.

637 Kurosaka, K., Takahashi, M., Watanabe, N. & Kobayashi, Y. 2003. Silent Cleanup of Very Early  
638 Apoptotic Cells by Macrophages. *Journal of Immunology*, 171, 4672-4679.

639 Lamagni, T. L., Darenberg, J., Luca-Harari, B., Siljander, T., Efstratiou, A., Henriques-Normark, B.,  
640 Vuopio-Varkila, J., Bouvet, A., Creti, R., Ekelund, K., Koliou, M., Reinert, R. R., Stathi, A.,  
641 Strakova, L., Ungureanu, V., Schalén, C., Jasir, A., Ioannou, Y., Kriz, P., Motlova, J.,  
642 Hammerum, A., Kaltoft, M. S., Iivonen, J., Loubinoux, J., Mihaila, L., Van Der Linden, M.,  
643 Lütticken, R., Papaparaskivas, J., Zachariadou, L., Baldassarri, L., Orefici, G., Straut, M.,  
644 Norrby-Teglund, A., Keshishian, C. & Neal, S. 2008. Epidemiology of severe *Streptococcus*  
645 *pyogenes* disease in Europe. *Journal of Clinical Microbiology*, 46, 2359-2367.

646 Larock, C. N. & Nizet, V. 2015. Inflammasome/IL-1 $\beta$  responses to streptococcal pathogens. *Frontiers*  
647 *in Immunology*, 6.

648 Lioy, V. S., Pratto, F., De La Hoz, A. B., Ayora, S. & Alonso, J. C. 2010. Plasmid pSM19035, a model to  
649 study stable maintenance in Firmicutes. *Plasmid*, 64, 1-17.

650 Loh, J. M. S. & Proft, T. 2013. Toxin-antitoxin-stabilized reporter plasmids for biophotonic imaging of  
651 Group A streptococcus. *Applied Microbiology and Biotechnology*, 97, 9737-9745.

652 Lundqvist-Gustafsson, H. & Bengtsson, T. 1999. Activation of the granule pool of the NADPH oxidase  
653 accelerates apoptosis in human neutrophils. *Journal of Leukocyte Biology*, 65, 196-204.

654 Ly, D., Taylor, J. M., Tsatsaronis, J. A., Monteleone, M. M., Skora, A. S., Donald, C. A., Maddocks, T.,  
655 Nizet, V., West, N. P., Ranson, M., Walker, M. J., McArthur, J. D. & Sanderson-Smith, M. L.  
656 2014. Plasmin(ogen) Acquisition by Group A Streptococcus Protects against C3b-Mediated  
657 Neutrophil Killing. *Journal of Innate Immunity*, 6, 240-250.

658 Maamary, P. G., Sanderson-Smith, M. L., Aziz, R. K., Hollands, A., Cole, J. N., McKay, F. C., McArthur, J.  
659 D., Kirk, J. K., Cork, A. J., Keefe, R. J., Kansal, R. G., Sun, H., Taylor, W. L., Chhatwal, G. S.,  
660 Ginsburg, D., Nizet, V., Kotb, M. & Walker, M. J. 2010. Parameters governing invasive disease  
661 propensity of non-M1 serotype group A Streptococci. *Journal of Innate Immunity*, 2, 596-  
662 606.

663 Man, S. M. & Kanneganti, T. D. 2016. Converging roles of caspases in inflammasome activation, cell  
664 death and innate immunity. *Nature Reviews Immunology*, 16, 7-21.

665 McLaughlin, R. E. & Ferretti, J. J. 1995. Electroporation of Streptococci. *Methods in Molecular*  
666 *Biology (Clifton, N.J.)*, 47, 185-193.

667 Medina, E., Goldmann, O., Toppel, A. W. & Chhatwal, G. S. 2003a. Survival of *Streptococcus*  
668 *pyogenes* within host phagocytic cells: A pathogenic mechanism for persistence and  
669 systemic invasion. *Journal of Infectious Diseases*, 187, 597-603.

670 Medina, E., Rohde, M. & Chhatwal, G. S. 2003b. Intracellular survival of *Streptococcus pyogenes* in  
671 polymorphonuclear cells results in increased bacterial virulence. *Infection and Immunity*, 71,  
672 5376-5380.

673 Nelson, G. E., Pondo, T., Toews, K. A., Farley, M. M., Lindegren, M. L., Lynfield, R., Aragon, D., Zansky,  
674 S. M., Watt, J. P., Cieslak, P. R., Angeles, K., Harrison, L. H., Petit, S., Beall, B. & Van Beneden,  
675 C. A. 2016. Epidemiology of invasive group a streptococcal infections in the United States,  
676 2005-2012. *Clinical Infectious Diseases*, 63, 478-486.

677 Nguyen, G. T., Green, E. R. & Mecsas, J. 2017. Neutrophils to the ROScue: Mechanisms of NADPH  
678 oxidase activation and bacterial resistance. *Frontiers in Cellular and Infection Microbiology*,  
679 7.

680 Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y.,  
681 Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin,  
682 T. T., Yu, V. L. & Miller, D. K. 1995. Identification and inhibition of the ICE/CED-3 protease  
683 necessary for mammalian apoptosis. *Nature*, 376, 37-43.

684 Norrby-Teglund, A., Chatellier, S., Low, D. E., Mcgeer, A., Green, K. & Kotb, M. 2000. Host variation in  
685 cytokine responses to superantigens determine the severity of invasive group A  
686 streptococcal infection. *European Journal of Immunology*, 30, 3247-3255.

687 O'grady, K. a. F., Kelpie, L., Andrews, R. M., Curtis, N., Nolan, T. M., Selvaraj, G., Passmore, J. W.,  
688 Oppedisano, F., Carnie, J. A. & Carapetis, J. R. 2007. The epidemiology of invasive group A  
689 streptococcal disease in Victoria, Australia. *Medical Journal of Australia*, 186, 565-569.

690 O'loughlin, R. E., Roberson, A., Cieslak, P. R., Lynfield, R., Gershman, K., Craig, A., Albanese, B. A.,  
691 Farley, M. M., Barrett, N. L., Spina, N. L., Beall, B., Harrison, L. H., Reingold, A. & Van  
692 Beneden, C. 2007. The epidemiology of invasive group A streptococcal infection and  
693 potential vaccine implications: United States, 2000-2004. *Clinical Infectious Diseases*, 45,  
694 853-862.

695 O'neill, A. M., Thurston, T. L. M. & Holden, D. W. 2016. Cytosolic replication of group a Streptococcus  
696 in human macrophages. *mBio*, 7.

697 Power, C., Wang, J. H., Sookhai, S., Wu, Q. D. & Redmond, H. P. 2001. Proinflammatory effects of  
698 bacterial lipoprotein on human neutrophil activation status, function and cytotoxic potential  
699 in vitro. *Shock*, 15, 461-466.

700 Ryu, J. C., Kim, M. J., Kwon, Y., Oh, J. H., Yoon, S. S., Shin, S. J., Yoon, J. H. & Ryu, J. H. 2017.  
701 Neutrophil pyroptosis mediates pathology of *P. aeruginosa* lung infection in the absence of  
702 the NADPH oxidase NOX2. *Mucosal Immunology*, 10, 757-774.

703 Schneider, K. S., Groß, C. J., Dreier, R. F., Saller, B. S., Mishra, R., Gorka, O., Heilig, R., Meunier, E.,  
704 Dick, M. S., Ćiković, T., Sodenkamp, J., Médard, G., Naumann, R., Ruland, J., Kuster, B., Broz,  
705 P. & Groß, O. 2017. The Inflammasome Drives GSDMD-Independent Secondary Pyroptosis  
706 and IL-1 Release in the Absence of Caspase-1 Protease Activity. *Cell Reports*, 21, 3846-3859.

707 Skubitz, K. M., Campbell, K. D. & Skubitz, A. P. N. 1996. CD66a, CD66b, CD66c, and CD66d each  
708 independently stimulate neutrophils. *Journal of Leukocyte Biology*, 60, 106-117.

709 Sollberger, G., Strittmatter, G. E., Kistowska, M., French, L. E. & Beer, H. D. 2012. Caspase-4 is  
710 required for activation of inflammasomes. *Journal of Immunology*, 188, 1992-2000.

711 Sumby, P., Porcella, S. F., Madrigal, A. G., Barbian, K. D., Virtaneva, K., Ricklefs, S. M., Sturdevant, D.  
712 E., Graham, M. R., Vuopio-Varkila, J., Hoe, N. P. & Musser, J. M. 2005. Evolutionary origin  
713 and emergence of a highly successful clone of serotype M1 group A Streptococcus involved  
714 in multiple horizontal gene transfer events. *Journal of Infectious Diseases*, 192, 771-782.

715 Sumby, P., Whitney, A. R., Graviss, E. A., Deleo, F. R. & Musser, J. M. 2006. Genome-wide analysis of  
716 group A streptococci reveals a mutation that modulates global phenotype and disease  
717 specificity. *PLoS Pathogens*, 2, 0041-0049.

718 Svensson, N., Öberg, S., Henriques, B., Holm, S., Källenius, G., Romanus, V. & Giesecke, J. 2000.  
719 Invasive group A streptococcal infections in Sweden in 1994 and 1995: Epidemiology and  
720 clinical spectrum. *Scandinavian Journal of Infectious Diseases*, 32, 609-614.

721 Tart, A. H., Walker, M. J. & Musser, J. M. 2007. New understanding of the group A Streptococcus  
722 pathogenesis cycle. *Trends in Microbiology*, 15, 318-325.

723 Tecchio, C., Micheletti, A. & Cassatella, M. A. 2014. Neutrophil-derived cytokines: Facts beyond  
724 expression. *Frontiers in Immunology*, 5.

725 Tran, T. a. T., Grievink, H. W., Lipinska, K., Kluft, C., Burggraaf, J., Moerland, M., Tasev, D. & Malone,  
726 K. E. 2019. Whole blood assay as a model for in vitro evaluation of inflammasome activation  
727 and subsequent caspase-mediated interleukin-1 beta release. *PLoS ONE*, 14.

728 Tsatsaronis, J. A., Ly, D., Pupovac, A., Goldmann, O., Rohde, M., Taylor, J. M., Walker, M. J., Medina,  
729 E. & Sanderson-Smith, M. L. 2015. Group A Streptococcus Modulates Host Inflammation by

730                    Manipulating Polymorphonuclear Leukocyte Cell Death Responses. *Journal of Innate  
731                    Immunity*, 7, 612-622.

732                    Tsatsaronis, J. A., Walker, M. J. & Sanderson-Smith, M. L. 2014. Host Responses to Group A  
733                    Streptococcus: Cell Death and Inflammation. *PLoS Pathogens*, 10.

734                    Valderrama, J. A., Riestra, A. M., Gao, N. J., Larock, C. N., Gupta, N., Ali, S. R., Hoffman, H. M., Ghosh,  
735                    P. & Nizet, V. 2017. Group A streptococcal M protein activates the NLRP3 inflammasome.  
736                    *Nature Microbiology*, 2, 1425-1434.


737                    Walker, M. J., Hollands, A., Sanderson-Smith, M. L., Cole, J. N., Kirk, J. K., Henningham, A., McArthur,  
738                    J. D., Dinkla, K., Aziz, R. K., Kansal, R. G., Simpson, A. J., Buchanan, J. T., Chhatwal, G. S., Kotb,  
739                    M. & Nizet, V. 2007. DNase Sda1 provides selection pressure for a switch to invasive group A  
740                    streptococcal infection. *Nature Medicine*, 13, 981-985.

741                    Wang, Q., Imamura, R., Motani, K., Kushiyama, H., Nagata, S. & Suda, T. 2013. Pyroptotic cells  
742                    externalize eat-me and release find-me signals and are efficiently engulfed by macrophages.  
743                    *International Immunology*, 25, 363-372.

744                    Wierzbicki, I. H., Campeau, A., Dehaini, D., Holay, M., Wei, X., Greene, T., Ying, M., Sands, J. S.,  
745                    Lamsa, A., Zuniga, E., Pogliano, K., Fang, R. H., Larock, C. N., Zhang, L. & Gonzalez, D. J. 2019.  
746                    Group A Streptococcal S Protein Utilizes Red Blood Cells as Immune Camouflage and Is a  
747                    Critical Determinant for Immune Evasion. *Cell Reports*.


748

749 **Supplemental Information**




750 **Supplementary figure 1. The association of fluorescent GAS (GFP) to human neutrophils**  
751 **determined via flow cytometry.** (A) Primary neutrophil (PMN) 'Singlets' cell selection (FSC-A  
752 vs. FSC-H) and (B) viable 'PMNs' discrimination (FSC-A vs. SSC-A). (C) Representative histogram  
753 showing relative fluorescence (GFP) of GAS infected neutrophils and gating for the selection of  
754 GAS-neutrophil association. (D) Rate of ROS production by neutrophils between 30-60 min (n=6  
755 donors). (E) GAS killing by human neutrophils is inhibited at 30 min following pre-incubation  
756 with actin polymerising molecule cytochalasin D (n=4 donors, Sidak's multiple comparison).  
757 Results are the pooled means $\pm$ SD (of triplicate measurements for panels D and E). \*\*p<0.01,  
758 \*\*\*p<0.001.

759




760 **Supplementary figure 2. Quantification of protein bands in human neutrophil lysates**  
761 **identified through immunoblotting.** (A) Caspase-3 p17, (B) caspase-1 full-length, (D) caspase-  
762 1 p46 and (D) caspase-4 immunoblots were imaged then analysed using ImageJ where area under  
763 the curve was normalised over total protein. Results are the means $\pm$ SD where 3 donors were  
764 used. \* $p$ <0.05, \*\* $p$ <0.01, \*\*\* $p$ <0.001 and \*\*\*\* $p$ <0.0001, with black asterisks denoting significance  
765 to control and grey asterisks between 5448 and 5448AP.

766



767 **Supplementary figure 3. Human neutrophils were assessed for the activation of caspase-1**  
768 **and release of cytokines via flow cytometry.** (A) Primary neutrophil (PMN) 'Singlet' cell  
769 selection (FSC-A vs. FSC-H) and (B) viable 'PMNs' discrimination (FSC-A vs. SSC-A). (C)  
770 Representative plot showing unstained and GAS infected neutrophils (Singlets/PMNs) with  
771 FLICA (FAM-YVAD-FMK) fluorescence. Gating strategy for LEGENDplex cytometric bead assay  
772 where (D) beads A and B were gated (FSC-A vs. SSC-A). Gates for beads A (shown) and B were  
773 assessed for (E) PE vs. APC fluorescence where cytokines had unique APC fluorescence and  
774 expression was measured via PE fluorescence when compared to a standard curve.

775



776 **Supplementary figure 4. Flow cytometric sequential gating strategy for identification of**  
777 **murine neutrophils determining caspase-1 activation.** (A) Primary 'Singlets' cell selection  
778 (FSC-A vs. FSC-H) and (B) 'Cells' discrimination (FSC-A vs. SSC-A) of murine blood and lavage  
779 fluid. 'Cells' were further gated upon (C) CD45-BV421 expression and (D) CD11b-PE/Cy5  
780 expression. Neutrophils (PMNs) were defined as (E) Ly-6G-PE<sup>+</sup> cells from the CD45+/CD11b+  
781 population. Neutrophils were assessed for (F) caspase-1 activation using FLICA 660 (660-YVAD-  
782 FMK).